Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS

The objective of this study is to compile real-world outcomes of Boston Scientific commercially approved radiofrequency (RF) ablation systems used in the central nervous system (CNS) for use in functional neurosurgery.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Parkinson Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Dyskinesias Dystonia Essential Tremor Movement Disorders Nervous System Diseases Neurodegenerative Diseases Neurologic Manifestations Parkinsonian Disorders Pathological Conditions, Signs and Symptoms Signs and Symptoms Synucleinopathies

Sex eligibility

All sexes

Study type

Observational

Primary location

Uniklinik Köln, Cologne, Germany

About this study

The objective of this study is to compile real-world outcomes of Boston Scientific Corporation commercially approved radiofrequency (RF) ablation systems used in the central nervous system (CNS) for use in functional neurosurgery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Study candidate is scheduled to be treated with a commercially approved Boston Scientific RF system for pain or for CNS applications per local Directions for Use (DFU)
Signed a valid, IRB/EC/REB-approved informed consent form

Exclusion criteria

Meets any contraindications per locally applicable Directions for Use (DFU)
Currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain relief or to complete study assessments

Treatment and study plan

Radiofrequency Ablation

Device

Radiofrequency Ablation used in the central nervous system (CNS) in functional neurosurgery

Primary outcomes

Change in patient's quality of life (QoL) during the study as compared with baseline

Time frame: Up to 24-Months

Change in quality of life assessments during the study as compared with baseline

Study contacts

Contact information is provided by the study sponsor or research team.

Diane Keesey

CONTACT

[email protected]

855-213-9890

Stephanie Delvaux

CONTACT

[email protected]

855-213-9890

Sponsors and collaborators

Lead sponsor

Boston Scientific Corporation

Industry

Registry information

Official study title

Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System

Important dates

Study start: 2024
Primary completion: 2035
Study completion: 2035
First posted: Aug 14, 2024
Registry last updated: Jul 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting